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Abstract
Variations in the Crumbs homolog-1 (CRB1) gene lead to autosomal recessive retinal dys-
trophies such as early-onset retinitis pigmentosa (RP) and Leber congenital amaurosis 
(LCA). No treatment is yet available for these patients. Adeno-associated virus (AAV) 
mediated gene therapy for hereditary retinal diseases holds great promise proven by the 
large number of active clinical trials. We here summarized the knowledge about the local-
ization and function of CRB1 in the retina and the main pathological features resulting 
from loss of CRB1 function in humans and in rodents. This know-how is being applied 
to design and develop AAV gene therapy vectors for the treatment of CRB1-Hereditary 
retinopathies. Knowing which cell types express the CRB proteins, the possible redun-
dancy of function between CRB1 and CRB2, and the AAV tropism in the human retina, 
will allow us to rationalize about the AAV capsid, promoter and route of administration 
that should be used in the AAV vector in order to efficiently and specifically deliver CRB1 
or CRB2 into the human retina.
Keywords: crumbs homolog-1 (CRB1), retinitis pigmentosa, Leber congenital 
amaurosis, gene therapy, adeno-associated virus (AAV)
1. Introduction
A new generation of medicines emerged in 2012 with the first ever European market autho-
rization of Glybera (alipogene tiparvovec), an adeno-associated virus (AAV) gene therapy 
medicine for the treatment of a rare inherited autosomal recessive lipid disorder, lipoprotein 
lipase deficiency. Five years later the company did not seek for renewal of the marketing 
authorization for Glybera due to patient’s lack of demand [1]. Despite the marketing failure 
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Targeted 
disease
AAV serotype Promoter Gene Delivery 
route
Volume 
injected
Dosage ClinicalTrials.
gov Identifier
Ref.
LCA AAV4 RPE65 hRPE65 Subretinal 400 or 
800 μL
1.22 × 1010 
vg
4.8 × 1010 vg
NCT01496040 [17]
AAV2 CBA hRPE65 Subretinal 450 μL 1.8 × 1011 vg
6 × 1011 vg
NCT00749957 [18, 
19]
AAV2 hRPE65 hRPE65 Subretinal up to 
1 mL
up to 
3 × 1012 vg
NCT00643747 [4, 
20]
AAV2 CBSB hRPE65 Subretinal 150–
300 μL
8.94 × 109
3.58 × 1010 
vg
NCT00481546 [21]
AAV2 CBA hRPE65v2 Subretinal 150 μL 1.5 × 1010 vg
4.8 × 1010 vg
1.5 × 1011 vg
NCT00999609 [22]
Choroideremia AAV2 CBA REP1 Subretinal 60–100  
μL
1010–1011 vg NCT01461213 
NCT02407678 
NCT02077361
[5]
AAV2 NR hCHM Subretinal NR NR NCT02341807 NR
RP (RLBP1) AAV8 sRLBP1 
CPK850
hRLBP1 Subretinal NR NR NCT03374657 [23]
RP (PDE6B) AAV5 RK hPDE6B Subretinal NR NR NCT03328130 [24]
RP (MERTK) AAV2 VMD2 hMERTK Subretinal NR NR NCT01482195 [25]
X-linked RP NR NR RPGR Subretinal NR NR NCT03116113 NR
AAV2tYF GRK1 RPGR Subretinal NR NR NCT03316560 [26, 
27]
Achromatopsia AAV8 NRx hCNGA3 Subretinal NR 1 × 1010 vg
5 × 1010 vg
1 × 1011 vg
NCT02610582 NR
AAV8 hCAR CNGB3 Subretinal NR NR NCT03001310 NR
AAV2tYF PR1.7 CNGA3 Subretinal NR NR NCT02935517 [28]
AAV2tYF PR1.7 CNGB3 Subretinal NR NR NCT02599922 [29]
X-linked 
retinoschisis
AAV8 scRS/
IRBP
shRS Intravitreal NR NR NCT02317887 [30, 
31]
AAV2tYF CB hRS1 Intravitreal NR NR NCT02416622 [32]
Leber 
hereditary 
optic 
neuropathy 
(LHON)
scAAV2 
(Y444,500,730F)
CMV/
CBA
P1ND4v2 Intravitreal 200 μL 5.00 × 109 
vg
2.46 × 1010 
vg
1.0 × 1011 vg
NCT02161380 [8, 
33]
AAV2 CMV ND4 Intravitreal 90 μL 3 × 1010 vg
9 × x1010 vg
1.8 × 1011 vg
NCT02064569
NCT02652767
NCT02652780
NCT03293524
[34, 
35]
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of Glybera, the use of AAV gene therapy in the eye is very attractive since the marketing 
prospects look better for the small amounts of AAV medicine to be transferred into the retinal 
tissue or retinal pigment epithelium. The eye is well accessible for surgery and allows direct 
observation, in vivo, of the retinal tissue in microscopic detail. Moreover, the eye is considered 
an immune-privileged tissue. Therefore, the risks of an immune response against the virus 
and/or the transgene itself are reduced. The local application in the “compartmentalized” eye 
of low amounts of AAV drug will minimize side effects expected if systemically applied at 
high doses [2]. But most importantly, potential drug efficacy for retinal orphan diseases can 
be efficiently proven thanks to a plethora of non-invasive retinal investigation techniques.
At the end of 2017, Luxturna (voretigene neparvovec-rzyl) became the first FDA-approved 
AAV gene therapy medicine for patients with hereditary retinal disease caused by biallelic 
RPE65 gene mutations [3, 4]. The market approvals of the first gene therapy medicines in 
Europa and in the USA paved the road to similar programs, reflected on the large num-
ber of clinical trials registered on the ClinicalTrials.gov website using AAVs as a delivery 
strategy to treat hereditary retinal diseases such as choroideremia (CHM or REP-1) [5], 
achromatopsia (CNGA3) [6], wet age-related macular degeneration (AMD) (VEGFR1/FLT 
and a gene encoding soluble anti-VEGF protein) [7], Leber hereditary optic neuropathy 
(LHON) (ND4) [8], autosomal recessive retinitis pigmentosa (arRP) (MERTK) [9], X-linked 
RP (RPGR) [10], RP (PDE6B) [11] and (RLBP1) [12] and X-linked Retinoschisis (RS1) [13, 14] 
(Table 1). Developing an AAV gene therapy to treat patients with mutations in the Crumbs 
homolog-1 (CRB1) gene was particularly challenging due to its large cDNA (4.2 kb) which 
approached the packaging limit of the AAV genome (~4.7–4.9 kb). Thus, to build an AAV 
vector that allowed efficient packaging of the human CRB1 cDNA, the use of a short pro-
moter (<350 bp) and a short synthetic polyadenylation sequence was required to efficiently 
express the CRB1 protein in vivo. Codon optimization of the CRB1 cDNA was used to 
achieve sufficient levels of expression [15]. A second strategy that implied the replacement 
of CRB1 by its structural and functional family member CRB2 was used to overcome the 
size limitation and potential toxicity due to expression of CRB1. CRB2 cDNA was only 
Targeted 
disease
AAV serotype Promoter Gene Delivery 
route
Volume 
injected
Dosage ClinicalTrials.
gov Identifier
Ref.
Age-Related 
Macular 
Degeneration 
(AMD)
AAV2 CMV sFLT01 Intravitreal 100 μL 2 × 108 vg
2 × 109 vg
6 × 109 vg
2 × 1010 vg
NCT01024998 [36]
AAV8 NR soluble 
anti-VEGF
Subretinal NR 3 × 109 vg
1 × 1010 vg
6 × 1010 vg
NCT03066258 NR
CBA: chicken β-actin promoter (CBA); CBSB: Hybrid modified short cytomegalovirus (CMV) enhancer and chicken 
β-actin promoter (CBA); GRK1: G protein-coupled receptor kinase; hCAR: human cone arrestin; NR: not reported; PR1.7: 
1.7-kb L-opsin promoter; REF: References; RK: Rhodopsin kinase; scRS/IRBP: Retinoschisin/interphotoreceptor retinoid 
binding protein; VMD2: Vitelliform macular dystrophy-2.
Table 1. Summary of the clinical trials for retinopathies using AAV as delivery system registered on ClinicalTrials.gov 
database.
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3.85 kb in size and gave more flexibility to design the AAV gene therapy vector in terms 
of promoter sequence size, polyadenylation sequence and other optimized sequences that 
stabilized the transcript [16].
2. CRB1-Hereditary retinopathies
More than 240 different mutations in the CRB1 gene have been described so far (http://
www.LOVD.nl/CRB1). These gene variations are associated with a wide variety of retinal 
dystrophies, including autosomal recessive retinitis pigmentosa (RP), Leber congenital 
amaurosis (LCA), cone-rod dystrophy, isolated macular dystrophy and foveal retinoschisis 
[37]. Furthermore, mutations in CRB1 are responsible for 7–17% of all the LCA cases and 
for approximately 3–9% of all cases of RP [38, 39]. Retinitis pigmentosa type 12 (RP12) due 
to mutations in the CRB1 gene was initially characterized by RP with preservation of para-
arteriolar retinal pigment epithelium (PPRPE), progressive visual field loss starting from the 
first decades of life, and early macular involvement. Later on it became clear that RP12 com-
monly presents early-onset retinitis pigmentosa, hyperopia and optic disc drusen, with or 
without PPRPE [37, 40, 41]. Leber congenital amaurosis type 8, due to mutation in the CRB1 
gene (LCA8), is a severe form of retinal dystrophy characterized by roving eye movements or 
nystagmus, nonrecordable or severely reduced cone and rod electroretinography amplitudes 
and severe loss of vision within the first years of life. Retinas of LCA8 patients with CRB1 
mutations are about 1.5 times thicker than normal retinas, while retinas of patients with LCA 
due to mutations in other genes such as RPE65 or GUCY2D are thinner [42]. In addition, LCA8 
retinas showed abnormal retinal architecture suggesting that loss of CRB1 function might 
interrupt the naturally occurring process of proliferation, apoptosis and cell migration during 
retinal development [42–44].
No treatment is yet available for CRB1-associated retinal dystrophies. We achieved proof-
of-concept for retinal CRB1 gene therapy, using an AAV9-CMV-hCRB2 vector in two mouse 
models. A first model lacked CRB1 and had reduced levels of CRB2 in Müller glial cells and 
photoreceptors, and a second model lacked CRB2 from Müller glial cells and photoreceptors 
[16]. These two pre-clinical studies opened the perspective for therapeutic trials for human 
CRB1-associated dystrophies.
Intriguingly, there is no clear genotype–phenotype correlation for CRB1 mutations [45]. This 
fact associated with the large spectrum of retinal dystrophies observed in patients with muta-
tions in the CRB1 gene [37], reinforced the need to study in detail the clinical features and 
natural disease progression of CRB1-associated retinal dystrophies before moving towards 
a clinical trial. This knowledge is required to establish patient eligibility criteria and clinical 
outcomes for the forthcoming clinical trial.
2.1. The CRB1-complex in the retina
In the developing mouse retina, the retinal neuroepithelium is composed of multipotent reti-
nal progenitor cells that differentiate in a time-dependent manner, giving rise to six major 
types of neuronal and one type of glial cells. The first cell type to be generated from the 
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progenitors are the ganglion cells, followed in overlapping sequential phases by horizontal 
cells, cone photoreceptors, amacrine cells, rod photoreceptors, bipolar cells and the Müller 
glial cells. The seven retinal cell types organize or “laminate” in three orderly distinct nuclear 
layers divided by two plexiform layers [46]. The CRB complex plays a crucial role during 
retinogenesis by the establishment of polarity, adhesion, retinal lamination and restricting 
proliferation and apoptosis of progenitors and the number of late born cells such as rod pho-
toreceptors, bipolar cells, late-born amacrine cells and Müller glial cells [47–52].
The CRB family in mammals consists of three members CRB1, CRB2 and CRB3. Both the CRB1 
and CRB2 have a large extracellular domain with epidermal growth factor-like and laminin-
A globular domains, a single transmembrane domain and a short intracellular C-terminal 
domain. The C-terminal domain of 37 amino acids has a single FERM-protein-binding motif 
juxtaposed to the transmembrane domain and a single C-terminal PDZ protein-binding motif 
[53–55]. While CRB3, the third family member, contains the transmembrane and C-terminal 
domain but is very short in length since it lacks the large extracellular domain. The C-terminal 
PDZ motifs of CRB proteins bind to the PDZ domain of PALS1 (also called MPP5). PALS1 
binds via its N-terminal L27 domain to the L27 domain of the multiple PDZ proteins PATJ 
and MUPP1 [56]. The multi-adapter protein PALS1 recruits MPP3 and MPP4 to the subapical 
protein complex at the so called subapical region adjacent to adherens junctions at the outer 
limiting membrane [57, 58]. Loss of the CRB1, CRB2, PALS1, or MPP3 but not MPP4 resulted in 
disruption of adhesion between photoreceptors and Müller glial cells. In summary, the core of 
the retinal CRB-complex is composed of CRB1, CRB2, PALS1, PATJ, MUPP1, and MPP3 [52, 59].
In the embryonic mouse retina, CRB1, CRB2, PALS1, PATJ and MUPP1 are expressed at the 
subapical region adjacent to the adherens junctions of the retinal progenitor cells [49]. In the 
adult mouse retina, CRB2 is present at the subapical region in photoreceptors and Müller glial 
cells. The mouse Crb1 gene transcript is expressed in photoreceptors and Müller glial cells but 
expression of the CRB1 protein is limited to the subapical region of Müller glial cells [60, 61]. 
CRB3 has a broader expression pattern being located at the subapical region in both photore-
ceptors and Müller glial cells [52, 60], at the photoreceptor inner segments and photoreceptor 
synaptic terminals and at sub-populations of amacrine and bipolar cells in the inner plexiform 
layer [62]. The expression patterns of CRB1 and CRB2 observed in the mouse retina do in part 
match with the ones observed in the human retina. In the first trimester human fetal retina, 
CRB2 but not CRB1 is expressed at the subapical region. While in the second trimester CRB1, 
CRB2 and PALS1 localize at the subapical region. A similar expression pattern is observed in 
early (differentiation day 28) versus late (differentiation day 160) human induced pluripo-
tent stem cells (iPSCs)-derived retinas [63]. Immunoelectron microscopic protein localization 
studies performed on adult human retinas, collected at two to 3 days post-mortem, showed 
CRB1 and CRB2 localization at the subapical region of Müller glial cells as found in the mouse 
retina. Human CRB1 localized also at the subapical region in photoreceptor cells, whereas 
human CRB2 localized at vesicles in the photoreceptor inner segments some distance away 
from the subapical region [52, 60] (Figure 1).
Interestingly, the overexpression of human CRB2 protein specifically in mouse photoreceptors 
that lacked endogenous mouse CRB2 in photoreceptors and Müller glial cells, caused aber-
rant localization of human CRB2 predominantly at vesicles in photoreceptor inner segments 
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at a distance from the subapical region. However, when expressed in both photoreceptors 
and Müller glial cells, human CRB2 localization was restricted to the subapical region, which 
suggested that expression of CRB2 in both cells types might be required for proper protein 
localization and function [16].
2.2. Animal models for CRB1-retinopathies
Animal models able to recapitulate features of the CRB1-retinopathies are of value to under-
stand the molecular mechanism behind retinopathies and to test new AAV gene therapy 
vectors. Over the recent years several rodent models were described in the literature. The 
retinal phenotypes observed in these animals mimic the wide spectrum of clinical features as 
described in CRB1-patients, including early and late onset RP, LCA and telangiectasia [44, 49, 
50, 52, 64–67]. The onset and severity of the phenotype observed in these animal models seem 
closely associated with the total levels of the CRB proteins in the different cell compartments. 
The available models can be grouped into three major categories:
a. late onset-RP: homozygous knockout Crb1 [52], hemizygous knockin Crb1C249W/− [67] and 
homozygous naturally occurring mutant Crb1rd8 [66] mice showed, at foci, loss of integrity 
of the outer limiting membrane, with protrusions of rows of photoreceptor nuclei into the 
inner- and outer segments layer and ingression of photoreceptor nuclei into the photore-
ceptor synaptic layer. Microglial cell infiltration and upregulation of glial fibrillary acidic 
protein (GFAP) were observed at the foci of photoreceptor dysplasia. Conditional abla-
tion of Crb2 specifically in Müller glial cells resulted in disruptions at the outer limiting 
Figure 1. Model depicting the localization of CRB1 and CRB2 proteins in the human retina at 2 days post-mortem. 
CRB proteins are present at the subapical region above the adherens junctions between Müller glial cells, between 
photoreceptor and Müller glial cells and between photoreceptor cells. CRB1 is located in both Müller glial cells and cone 
and rod photoreceptor cells at the subapical region. CRB2 is located in Müller glial cells at the subapical region, and in 
photoreceptors at vesicles in the inner segments at a distance from the subapical region.
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membrane and ectopic photoreceptor nuclei in the inner- and outer segment layer [50]. 
The morphological abnormalities observed in all these models do not lead to a decrease in 
electrical retinal function.
b. early onset-RP: ablation of Crb2 from retinal progenitor cells, and consequent loss of 
CRB2 in cone and rod photoreceptors and Müller glial cells [47, 49] or ablation of Crb2 
specifically in immature photoreceptors [50] leads to disruptions at the outer limiting 
membrane during late-stage embryonic development resulting in abnormalities in retinal 
lamination, severe retinal degeneration and early loss of retinal function. More recently, 
a naturally occurring substrain of Brown Norway rats (BN-J) was described as a model 
for retinal telangiectasia due to homozygous variations in the Crb1 gene. Interestingly the 
retinal phenotype observed in this Crb1 rat strain differs from the phenotype observed in 
the Crb1 knockout mice. The Crb1 rat displays retinal dysplasia at early postnatal days, 
leading to early-onset disruption of photoreceptor synapses and subsequent loss of reti-
nal function at 1 month of age and near to complete photoreceptor cell death at 6 months 
of age [64].
c. LCA: mouse retinas with loss of CRB1 and CRB2 proteins from retinal progenitor cells 
showed lack of a proper retinal lamination with loss of a photoreceptor synaptic layer, 
intermingling of photoreceptor nuclei with the nuclei of inner nuclear layer cells, and 
early loss of retinal function [44].
The lack of a genotype–phenotype correlation in humans might correlate with the different 
retinal phenotypes as observed in mice with lowered levels of CRB1 and/or CRB2 in retinal 
progenitors, photoreceptors and Müller glial cells. Cumulative data suggest that not only the 
levels of CRB1 are important for the pathogenesis observed in humans but also the total levels 
of CRB1 and CRB2 proteins. Or that the levels of functional CRB2 variants in retinal progeni-
tors, photoreceptors or Müller glial cells might play a role in determining the severity of the 
retinal dystrophy caused by mutations in the CRB1 gene.
3. Adeno-associated virus (AAV) biology
Adeno-associated virus belongs to the parvovirus family, but is placed in the genus 
Dependovirus since it is dependent on co-infection with other viruses, mainly adenoviruses, 
in order to replicate. AAV is a small, non-enveloped single-stranded DNA virus. The genome 
of the AAV is approximately 4.7 kb and has three open reading frames to express the rep 
(Replication), cap (Capsid) and assembly activating protein (aap) (Assembly) genes, flanked 
by two 145 nucleotide-long inverted terminal repeats (ITRs). The ITRs self-assemble into hair-
pin structures required for genome replication, integration and encapsidation. The rep gene 
encodes four proteins (Rep78, Rep68, Rep52 and Rep40), which are required for viral genome 
replication and packaging. While cap gene transcripts gives rise to the viral capsid proteins, 
virion protein 1 (VP1), VP2 and VP3, with molecular weights of 87, 72 and 62 kDa, respectively. 
These capsid proteins assemble into an icosahedral symmetry protein shell of 60 subunits, in 
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a molar ratio of 1:1:10 (VP1:VP2:VP3). The aap gene encodes the assembly-activating protein 
(AAP) that is thought to have a scaffolding function for capsid assembly [68]. Wild-type AAV 
integrates into the human host genome at a specific site, AAVS1 on chromosome 19.
In gene therapy a recombinant AAV (rAAV) and not the wild-type AAV are used. In rAAV the 
viral genome required for viral replication, the rep and cap genes, and the element required 
for site-specific integration are deleted. A sequence containing a promoter, a 5′-untranslated 
region, the cDNA of a transgene of interest, and a 3′-untranslated region containing a poly-
adenylation site are then inserted in between the AAV vector containing the two ITRs. To 
produce AAV particles from the AAV gene therapy plasmid in a human cell line, the rep and 
cap genes are supplied in trans on a helper plasmid along with helper genes from adenovirus 
(E4, E2a and VA) necessary for replication.
The major advantages of the use of rAAVs are the safety profile, low immunogenicity, lack 
of toxicity and the property that the rAAV genomes do not integrate into the host genome. 
The rAAV capsid enters the cells by receptor-mediated endocytosis, the rAAV genomes 
are processed into nuclear episomal structures and are maintained extrachromosomally. 
Dependent on the gene therapy vector used, and the life span of the targeted cell, the rAAV 
genomes can express a transgene for more than 10 years. AAV vectors also have the ability 
to transduce non-dividing cells, including non-dividing retinal neurons like photoreceptors. 
One major disadvantage of the rAAV technology is the size limitation of the total DNA that 
can be efficiently packaged in the AAV vector (4.7–4.9 kb) which makes it difficult to design 
AAV-mediated gene therapy for larger genes (≥ 4 kb). The development of dual and triple 
AAV vectors with a maximum transfer capacity of around 9 and 14 kb, respectively, might in 
the future overcome in part this limitation [69].
The generation of a gene therapy vector able to deliver CRB1 is particularly challenging due 
to its large size of cDNA (4.2 kb). To assemble the gene therapy vector, the 4.2 kb CRB1 cDNA 
and the two ITR sequences (0.29 kb) need to be added which make up to 4.49 kb. Therefore, 
only 0.2–0.41 kb space is left for the promoter and polyadenylation sequences. Although chal-
lenging it was shown that it is possible to efficiently package human CRB1 cDNA in AAV 
vectors and to express CRB1 protein in vivo [15, 16]. Another strategy to overcome the size 
limitation is to use the 3.85 kb CRB2 cDNA as replacement [16].
3.1. Gene delivery in the retina using AAVs
The eye offers a set of unique features for the application of gene therapy vectors. The eye 
is a small, compartmentalized, immunoprivileged, paired organ and easily accessible using 
minimally invasive techniques. There are also high resolution functional and structural 
diagnostics, such as, optical coherence tomography, scanning laser ophthalmoscopy and 
electroretinography, as well as psychophysical tests such as microperimetry, kinetic perim-
etry, visual acuity testing, and multi-luminance mobility test (MLMT) in the ophthalmology 
field that allow to examine the eye/retina structure and to test as well retinal function and 
vision. Gene therapy vectors for retinal disease can be delivered mainly by two routes: sub-
retinally into the “subretinal space” between the neural retina and the RPE, or intravitreally, 
into the vitreous body, both approaches are described below. The administration route is an 
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important parameter to take into consideration in the testing of gene therapy vectors, together 
with the selection of the AAV capsid and promoter since all these parameters have effects on 
the tropism of the vectors.
3.2. Route of delivery
3.2.1. Subretinal injection
In pre-clinical studies performed in rodents ab externo subretinal injections are commonly 
performed [16, 70]. This method uses a small needle (34 gauge) to penetrate (ab externo) the 
sclera at the limbus and under direct observation the needle can be guided through the retina 
to create a subretinal space between the retinal pigment epithelium and the outer limiting 
membrane. Normally, a volume of 1 μL is injected to form an injection fluid bleb that tran-
siently detaches a large portion of neural retina from the RPE in one single injection. Incorrect 
surgery might cause cataract due to damage to the lens. It is also common to have a large 
volume of backflow of injected AAV particles when the injection needle is retracted.
Subretinal injections in human can be performed using the “single-step” or the “two-step” 
approach [71]. With the “single-step” approach the fluid, containing the gene therapy vector, 
is directly delivered into the subretinal space without previous retinal detachment [22].
The “two-step” approach consists of first the generation of a bleb in the subretinal space 
by injection of a balanced salt solution (BSS), followed by injection of the therapeutic agent 
using a controlled flow rate [4, 5, 72]. The second approach offers several advantages like the 
possibility to better assess the direction of bleb spread as well as to minimize vector loss by 
misguided injection [71]. The subretinal surgery and injection is a specialized technique and 
can in principle be executed by surgeons operating an ophthalmic surgery robot to obtain 
most reproducible results. According to information collected from the different clinical tri-
als registered in the Clinicaltrials.gov database, a volume ranging from 60 to 1000 μL can be 
injected via this route (Table 1).
Subretinal injections seem the logical choice when RPE or photoreceptors are the target cells, 
since these cells will be in direct contact with the fluid containing the AAV particles. However, 
degenerating retinas at an advanced stage are often quite thin, with disruptions at the outer 
limiting membrane, loss of inner/outer segments and/or photoreceptor cells, neovasculariza-
tion and infiltration of microglial cells. All these features might lead to a reduction in the 
potential subretinal space between the neural retina and the RPE, or to leaking of the AAV 
vector to the choroid vasculature system and influence the AAV tropism. The retinal detach-
ment caused during the subretinal injection might potentially also either aggravate or allevi-
ate the processes of retinal degeneration.
3.2.2. Intravitreal injection
Intravitreal injection implies direct delivery into the space in the back of the eye called the 
vitreous cavity, which is filled with a jelly-like fluid called the vitreous humor gel. Intravitreal 
injections are generally limited to volumes of up to 2 μL in mice [15, 16, 73], while in rats the 
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volumes are limited to 3–5 μL [74]. The main surgical complications observed are cataract 
formation due to lens-induced damage and retinal perforation [75].
In humans intravitreal injections are generally performed under local anesthesia [71], by 
inserting a 30 gauge needle through the sclera at the pars plana region, 3.5–4 mm posterior 
to the limbus between vertical and horizontal muscles with limited reflux [71, 73]. In clinical 
trials volumes between 90 and 200 μL have been injected via this route (Table 1).
Intravitreal administration of AAV gene therapy might look tempting since it is an easier 
procedure with less potential surgical complications compared to the subretinal injection, 
especially when treating thinned degenerative retinas. However, administration of AAV 
intravitreally has its own caveats namely the difficulty of AAV capsids to cross the thick inner 
limiting membrane in the human retina and the current lack of AAV serotypes capable of 
transducing efficiently the human photoreceptors or RPE cells. Another obstacle is the poten-
tial AAV transduction and subsequent expression in other eye tissues, as for example, the 
ciliary body especially when using a ubiquitous promoter.
Pre-clinical studies in mice and rats showed that Müller glial cells can efficiently be infected 
after intravitreal administration of AAV2/6 or AAV2/shH10Y445F [15, 76], therefore these AAV 
capsids might be used to deliver CRB1 or CRB2 into Müller cells. AAV serotype shH10Y445F is 
however known to transduce efficiently the ciliary body epithelium when applied intravit-
really [16].
3.3. AAV capsids and cell type specific promoters
The existence of 11 natural AAV serotypes and derivatives that differ in their tropism, and the 
different types of cells they infect, makes AAV a very useful system to infect the various cell 
types of the retina. The cell specificity of the AAV vector can be further increased by using cell 
type specific promoters, for example RPE65 or VMD2 to drive expression in retinal pigment 
epithelium. Or by using e.g. the rhodopsin (RH), G protein-coupled receptor kinase 1 (GRK1), 
1.7-kb L-opsin promoter (PR1.7) or cone arrestin (hCAR) promoter to drive expression in 
rod and/or cone photoreceptors. Or using e.g. the RLBP1, GFAP or NR2E1 promoter to drive 
expression in Müller cells [17, 23, 24, 28].
Several pre-clinical studies showed the tropism and/or potency of the different capsids and 
promoter (cell specific or ubiquitous) in infecting retinal cell types such as RPE, photore-
ceptors and Müller glial cells. However, AAV tropism might differ in vivo between rodent 
species, dogs, non-human primates and human. AAV tropism is dependent of the route of 
administration, the stage of retinal development and severity of retinal dystrophy. Therefore, 
is quite difficult to extrapolate the data from pre-clinical studies performed in rodents directly 
to the human in vivo setting. To obtain evidence-based data for clinical gene therapy stud-
ies, researchers optimize culture protocols for human retinal organotypic cultures [77–79] or 
human iPSC-derived retinas to study the AAV tropism [80]. Recently, the capacity of differ-
ent AAV serotypes to infect and express in human retinal cells was studied in organotypic 
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cultures. This study suggested that serotypes AAV4, AAV5 and AAV6 were particularly effi-
cient at transducing photoreceptor cells, whereas serotype AAV8 displayed consistently low 
transduction of these cells [79, 81]. Actually several AAV serotypes and ubiquitous promoters 
or cell specific promoters are being used in clinical trials (Table 1), the results from these 
studies will provide us with important clues about the best promoters and capsids to use in 
the human retina.
In order to deliver CRB1 or CRB2 into rod and cone photoreceptor and Müller glial cells in 
the human retina an AAV capsid able to infect all the three cell types needs to be used in com-
bination with a promoter active in the same cells. Studies performed in mice suggested that 
a combination of AAV9 and a CMV promoter might be a possibility but further studies are 
required to test its suitability for human retinal cells [16]. Subretinal injection of expression vec-
tors packaged into serotypes AAV5 or AAV9 infect photoreceptors in vivo in macaques [82, 83]. 
Tropism studies in human retinal explants reported that AAV5 would be more efficacious than 
AAV9 [84]. Another strategy would be the use of one vector to deliver CRB1 or CRB2 specifi-
cally in Müller glial cells and a second vector to deliver specifically in photoreceptors. Besides 
regulatory and financial issues, the main technical issues here resides with the lack of a short 
promoter (≤ 300 bp) specific for Müller cells, and the lack of an AAV serotype that in human 
retina efficiently infects Müller glial cells upon intravitreal or subretinal injection.
4. Conclusion
In recent years the scientific progress in the field of gene therapy for inherited retinal dystro-
phies culminated in the first ever approved AAV gene therapy medicine to treat LCA patients 
carrying mutations in the RPE65 gene. The number of engineered AAV capsid variants and 
new promoters to drive expression in the different retinal cell types is raising at great speed 
allowing the design of more specific and more efficient viral vectors. Likewise, the number 
of clinical trials using AAV gene therapy is increasing at a similar rhythm, the data collected 
from these studies will be very useful for the development of similar therapies. Pre-clinical 
studies performed in mice demonstrated that AAV-mediated CRB2 gene augmentation ther-
apy might be a promising medicine to prevent progression of retinitis pigmentosa in patients 
with mutations in the CRB1 gene. In mice at mid-stage retinal disease CRB2 gene augmenta-
tion therapy successfully improved retinal morphology with preservation of photoreceptor 
cells and retinal function, therefore providing good perspectives for the forthcoming clinical 
trial in patients with RP due to mutations in CRB1.
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